LEADER 02425nam  2200613Ia 450 
001 9910783067203321
005 20230617032316.0
010   $a0-309-16641-1
010   $a1-280-17629-6
010   $a9786610176298
010   $a0-309-53098-9
035   $a(CKB)1000000000004081
035   $a(OCoLC)70772941
035   $a(CaPaEBR)ebrary10060421
035   $a(SSID)ssj0000280849
035   $a(PQKBManifestationID)11207293
035   $a(PQKBTitleCode)TC0000280849
035   $a(PQKBWorkID)10300800
035   $a(PQKB)10591686
035   $a(MiAaPQ)EBC3376849
035   $a(Au-PeEL)EBL3376849
035   $a(CaPaEBR)ebr10060421
035   $a(OCoLC)923266521
035   $a(EXLCZ)991000000000004081
100   $a20040925d2004      my             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aIntentional human dosing studies for EPA regulatory purposes$b[electronic resource] $escientific and ethical issues /$fCommittee on the Use of Third Party Toxicity Research with Human Research Participants, Science, Technology, and Law Program, Policy and Global Affairs Division, National Research Council of the National Academies
210   $aWashington, D.C. $cNational Academies Press$dc2004
215   $a1 online resource (226 p.)
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-09172-1 
320   $aIncludes bibliographical references.
606   $aHuman experimentation in medicine$xMoral and ethical aspects
606   $aHuman experimentation in medicine$xGovernment policy$zUnited States
606   $aMedical ethics
606   $aMedicine$xResearch$xMoral and ethical aspects
615  0$aHuman experimentation in medicine$xMoral and ethical aspects.
615  0$aHuman experimentation in medicine$xGovernment policy
615  0$aMedical ethics.
615  0$aMedicine$xResearch$xMoral and ethical aspects.
676   $a174.2/8
712 02$aNational Research Council (U.S.).$bPolicy and Global Affairs.
712 02$aNational Research Council (U.S.).$bCommittee on the Use of Third Party Toxicity Research with Human Research Participants.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910783067203321
996   $aIntentional human dosing studies for EPA regulatory purposes$93778077
997   $aUNINA